Home » Newsletters » BioWorld Science

BioWorld Science

May 9, 2019

View Archived Issues

Zoning affects tumor metabolism

RASER wire for cancer cells

Retinoic acid-induced protein 3, a marker of poor outcomes in esophageal cancer patients

NUP98 predicts poor outcomes in triple-negative breast cancer under anthracycline-based regimens

Scientists create model of congenital cytomegalovirus transmission after maternal reinfection

SEECASE trial finds efficacy of NOV-03 in treating dry eye disease

NEOLEV2 trial highlights the difficulty of treating neonatal seizures

First clinical data of an ARSB gene therapy for mucopolysaccharidosis type VI

Neuropore initiates phase I study of NPT-520-34

Phase I results presented for LY-3154207

Genetic knockout mice may be an improved model of neuropathic bladder

FDA allows IND application for phase I study of CB-03-10

Merck & Co. patents IDO1 inhibitors

Enrollment completed in second stage of phase II study of bemcentinib plus Keytruda in NSCLC

Unifying rare diseases may enable multiple treatments

Shionogi & Co. describes anti-influenza agents

ObsEva initiates phase III program for linzagolix in endometriosis-associated pain

IFM Tre discloses NLRP3 inflammasome inhibitors

First patient dosed in phase II trial of SRK-015 in type 2 and type 3 SMA

Phase II trial of 15-valent pneumococcal conjugate vaccine V-114 meets primary endpoint

Provention Bio reports phase Ib results for PRV-300 in ulcerative colitis

CJ HealthCare identifies JAK1 inhibitors

FDA clears IND for phase I/II trial of IDE-196 in tumors with GNAQ/11 mutations or PKC fusions

Texas State University discloses photoactivatable cancer prodrugs

Oyster Point studies long-term safety of OC-01 nasal spray in ONSET extension trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...